Compare RYZ & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYZ | CAPR |
|---|---|---|
| Founded | 1842 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2010 | 2011 |
| Metric | RYZ | CAPR |
|---|---|---|
| Price | $28.55 | $4.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | N/A | ★ $44.63 |
| AVG Volume (30 Days) | 482.7K | ★ 5.6M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.82% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $4,571,300,000.00 | N/A |
| Revenue This Year | $75.79 | N/A |
| Revenue Next Year | $2.17 | $3.31 |
| P/E Ratio | $68.60 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.34 | $2.96 |
| 52 Week High | $32.00 | $40.37 |
| Indicator | RYZ | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 52.83 | 16.61 |
| Support Level | $26.01 | $4.23 |
| Resistance Level | $29.08 | $6.54 |
| Average True Range (ATR) | 1.43 | 0.80 |
| MACD | -0.06 | 0.07 |
| Stochastic Oscillator | 50.07 | 7.90 |
Ryerson Holding Corp provides a metals service center, and value-added processor and is a distributor of industrial metals with operations in the United States, Canada, and Mexico. In addition to its North American operations, it conducts processing and distribution operations in China. It carries a full line of products in stainless steel, aluminum, carbon steel, and alloy steels and a limited line of nickel and red metals in various shapes and forms. The company has one operating and reportable segment, metals service centers. It derives substantially all of its sales from the processing and distribution of met. Geographically, the majority revenue is generated from the United States.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.